NVO Novo Nordisk A/S
Company Analysis
Latest News
Novo Nordisk Wins EU Backing for Wegovy Pill, Nearing First Oral Treatment
Novo Nordisk received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its oral semaglutide...
Novo Nordisk Reclaims Market Share, Oral Wegovy Prices Rival Compounded Drugs
U.S. doctors report a notable shift as patients transition from compounded GLP-1 medications to branded oral options. Patients are moving to Novo Nordisk’s...
Novo Nordisk Slumps, Facing Canadian Generics and Record Eli Lilly Data
Hims & Hers launched generic semaglutide on its Canadian telehealth platform on May 21, 2026. The company is using a version produced by Apotex following the...
Novo Nordisk loses Ozempic monopoly, generic rivals launch in Canada
Generic versions of semaglutide begin arriving in Canadian pharmacies this week. Health Canada approved these drugs from manufacturers Apotex and Dr. Reddy’s...
Novo Nordisk to Unveil Semaglutide MASH Data, Targeting 250 Million Patients
Novo Nordisk will present new data on semaglutide for metabolic dysfunction-associated steatohepatitis (MASH) at the European Association for the Study of the...
Novo Nordisk launches Wegovy pill globally, countering US pricing and generic rivals
Novo Nordisk plans to launch its oral weight-loss drug, Wegovy, in international markets later this year pending regulatory approvals. The company’s executive...
Novo Nordisk A/S Q1 2026 Earnings Preview: What Analysts Expect on May 06, 2026
Consensus forecasts peg Q1 revenue at $11.84 billion and EPS at $0.87, as the stock trades at $164.20 against an average analyst target of $188.50. Investors...